Nanoencapsulation of a ruthenium (ii) complex with triazolopyrimidine in liposomes as a tool for improving its anticancer activity against melanoma cell lines
M Fandzloch, A Jaromin, M Zaremba-Czogalla… - Dalton …, 2020 - pubs.rsc.org
Two types of ruthenium (II) complexes containing 1, 2, 4-triazolo [1, 5-a] pyrimidines of the
general formulas [RuCl2 (dmso) 3 (L)]((1)–(3)) and [RuCl2 (dmso) 2 (L) 2]((4)–(6)), where L …
general formulas [RuCl2 (dmso) 3 (L)]((1)–(3)) and [RuCl2 (dmso) 2 (L) 2]((4)–(6)), where L …
Pyridine ruthenium (III) complexes entrapped in liposomes with enhanced cytotoxic properties in PC-3 prostate cancer cells
A D'Amora, ME Cucciolito, R Iannitti, G Morelli… - Journal of Drug Delivery …, 2019 - Elsevier
The first aim of the present study is the development of a new ruthenium (III) complex,
belonging to NAMI-A class, with a potentially high cytotoxic ability. The presence of a fully …
belonging to NAMI-A class, with a potentially high cytotoxic ability. The presence of a fully …
Cationic liposomes as efficient nanocarriers for the drug delivery of an anticancer cholesterol-based ruthenium complex
Aiming for novel tools for anticancer therapies, a ruthenium complex, covalently linked to a
cholesterol-containing nucleolipid and stabilized by co-aggregation with a biocompatible …
cholesterol-containing nucleolipid and stabilized by co-aggregation with a biocompatible …
Significant increase of anticancer efficacy in vitro and in vivo of liposome entrapped ruthenium (II) polypyridyl complexes
Y Chen, W Li, Y Yang, R Zhong, H Hu, C Huang… - European Journal of …, 2023 - Elsevier
Two polypyridyl ruthenium (II) complexes [Ru (DIP) 2 (BIP)](PF 6) 2 (DIP= 4, 7-diphenyl-1, 10-
phenanthrolie, BIP= 2-(1, 1′-biphenyl-4-yl)-1H-imidazo [4, 5-f][1, 10] phenanthroline, Ru1) …
phenanthrolie, BIP= 2-(1, 1′-biphenyl-4-yl)-1H-imidazo [4, 5-f][1, 10] phenanthroline, Ru1) …
A liposome encapsulated ruthenium polypyridine complex as a theranostic platform for triple-negative breast cancer
Ruthenium coordination complexes have the potential to serve as novel theranostic agents
for cancer. However, a major limitation in their clinical implementation is effective tumor …
for cancer. However, a major limitation in their clinical implementation is effective tumor …
[HTML][HTML] Studies of anticancer activity in vitro and in vivo of iridium (III) polypyridyl complexes-loaded liposomes as drug delivery system
WY Zhang, F Du, M He, L Bai, YY Gu, LL Yang… - European journal of …, 2019 - Elsevier
Two iridium (III) polypyridyl complexes [Ir (ppy) 2 (HPIP)](PF 6)(Ir-1),[Ir (ppy) 2 (BHPIP)](PF
6)(Ir-2) and their liposomes Ir-1-Lipo and Ir-2-Lipo were synthesized and characterized by …
6)(Ir-2) and their liposomes Ir-1-Lipo and Ir-2-Lipo were synthesized and characterized by …
Ruthenium-based complex nanocarriers for cancer therapy
G Mangiapia, G D'Errico, L Simeone, C Irace… - Biomaterials, 2012 - Elsevier
A new organometallic ruthenium complex, named AziRu, along with three amphiphilic
nucleoside-based ruthenium complexes, ToThyRu, HoThyRu and DoHuRu, incorporating …
nucleoside-based ruthenium complexes, ToThyRu, HoThyRu and DoHuRu, incorporating …
Synthesis of terpolymer-lipid encapsulated diruthenium (II, III)-anti-inflammatory metallodrug nanoparticles to enhance activity against glioblastoma cancer cells
Novel formulations of diruthenium (II, III)-NSAID (NSAID, non-steroidal anti-inflammatory
drug) metallodrugs encapsulated into biocompatible terpolymer-lipid nanoparticles (TPLNs) …
drug) metallodrugs encapsulated into biocompatible terpolymer-lipid nanoparticles (TPLNs) …
Liposomes loaded with a dirhenium compound and cisplatin: preparation, properties and improved in vivo anticancer activity
Z Li, NI Shtemenko, DY Yegorova… - Journal of Liposome …, 2015 - Taylor & Francis
Liposomes loaded with the rhenium compound (bis-dimethylsulfoxido-cis-tetrachlorodi-μ-
pivalatodirhenium (III)(cis–Re2 ((CH3) 3CCOO) 2Cl4ċ2DMSO, I) and cisplatin in the molar …
pivalatodirhenium (III)(cis–Re2 ((CH3) 3CCOO) 2Cl4ċ2DMSO, I) and cisplatin in the molar …
Anticancer cationic ruthenium nanovectors: from rational molecular design to cellular uptake and bioactivity
G Mangiapia, G Vitiello, C Irace, R Santamaria… - …, 2013 - ACS Publications
An efficient drug delivery strategy is presented for novel anticancer amphiphilic ruthenium
anionic complexes, based on the formation of stable nanoparticles with the cationic lipid 1, 2 …
anionic complexes, based on the formation of stable nanoparticles with the cationic lipid 1, 2 …